CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
HGF Plasmidbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02016755
NCT02016755Phase 2Completed
CompareCT.gov

A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

AnGes USA, Inc.·interventional·Posted Dec 20, 2013·Updated Jan 22, 2021

In Brief

A Phase 2 clinical trial evaluating HGF Plasmid for Critical Limb Ischemia and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of the study is to confirm the feasibility of study procedures and the tolerability of a new dose regimen of AMG0001 in subjects with Critical Limb Ischemia (CLI)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Limb Ischemia, Vascular Diseases, Peripheral Arterial Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 20, 2013
Enrollment StartNov 1, 2013
Primary CompletionMar 31, 2018
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.5 years ago

Interventions

HGF Plasmidbiological

Intramuscular injection in the affected limb.